{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:37:07Z","timestamp":1790735827858,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.humpath.2016.09.003","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T17:15:56Z","timestamp":1474391756000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort"],"prefix":"10.1016","volume":"59","author":[{"given":"Margaret","family":"Cocks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephania M.","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Del Carmen Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo F.P.","family":"Ricardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni B.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Meeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alcides","family":"Chaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur L.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Netto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2016.09.003_bb0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.urolonc.2006.08.029","article-title":"Incidence trends in primary malignant penile cancer","volume":"25","author":"Barnholtz-Sloan","year":"2007","journal-title":"Urol Oncol"},{"key":"10.1016\/j.humpath.2016.09.003_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.humpath.2016.09.003_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2015.12.041","article-title":"Management of penile cancer","author":"Diorio","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.humpath.2016.09.003_bb0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2490-9-8","article-title":"Identifying the needs of penile cancer sufferers: a systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer","volume":"9","author":"Maddineni","year":"2009","journal-title":"BMC Urol"},{"key":"10.1016\/j.humpath.2016.09.003_bb0025","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.3892\/or.2015.3933","article-title":"The prognostic significance of PD-L1 in bladder cancer","volume":"33","author":"Huang","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.humpath.2016.09.003_bb0030","doi-asserted-by":"crossref","first-page":"12024","DOI":"10.18632\/oncotarget.7593","article-title":"CD274\/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity","volume":"7","author":"Straub","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2016.09.003_bb0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/cup.12728","article-title":"PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis","volume":"43","author":"Slater","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.humpath.2016.09.003_bb0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.09.003_bb0045","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(16)00654-1","article-title":"Role for anti\u2013PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma","volume":"387","author":"Netto","year":"2016","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.humpath.2016.09.003_bb0050","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science (NY, NY)"},{"key":"10.1016\/j.humpath.2016.09.003_bb0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","article-title":"Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer","volume":"58","author":"Leffers","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.humpath.2016.09.003_bb0060","first-page":"3","article-title":"Focus on TILs: prognostic significance of tumor-infiltrating lymphocytes in human melanoma","volume":"9","author":"Oble","year":"2009","journal-title":"Cancer Immun"},{"key":"10.1016\/j.humpath.2016.09.003_bb0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxw025","article-title":"Roles of regulatory T cells in cancer immunity","volume":"28","author":"Takeuchi","year":"2016","journal-title":"Int Immunol"},{"key":"10.1016\/j.humpath.2016.09.003_bb0070","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1464-410X.2010.10020.x","article-title":"FOXP3 and survival in urinary bladder cancer","volume":"108","author":"Winerdal","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.humpath.2016.09.003_bb0075","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/1078-0432.CCR-08-1296","article-title":"Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma","volume":"15","author":"Jensen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.09.003_bb0080","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/1078-0432.CCR-11-3216","article-title":"The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature","volume":"18","author":"deLeeuw","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.09.003_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.urology.2016.02.006","article-title":"Overexpression of insulin-like growth factor-1 receptor is associated with penile cancer progression","volume":"92","author":"Ball","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.humpath.2016.09.003_bb0090","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.humpath.2014.12.004","article-title":"Human papillomavirus infection and immunohistochemical p16 (INK4a) expression as predictors of outcome in penile squamous cell carcinomas","volume":"46","author":"Bezerra","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2016.09.003_bb0095","first-page":"89","article-title":"Practical methods for tissue microarray construction","volume":"103","author":"Fedor","year":"2005","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.humpath.2016.09.003_bb0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2015.02.032","article-title":"A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1\/PD-L1, and HLA-G","volume":"68","author":"Carosella","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2016.09.003_bb0105","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2016.09.003_bb0110","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2016.09.003_bb0115","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2016.09.003_bb0120","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"issue":"Suppl. 3","key":"10.1016\/j.humpath.2016.09.003_bb0125","first-page":"39","article-title":"Prognostic and predictive markers for the new immunotherapies","volume":"28","author":"Mahoney","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.humpath.2016.09.003_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2016.03.011","article-title":"Biomarkers for PD-1\/PD-L1 blockade therapy in non\u2013small-cell lung cancer: is PD-L1 expression a good marker for patient selection?","author":"Chae","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.humpath.2016.09.003_bb0135","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/modpathol.2016.64","article-title":"Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix","volume":"29","author":"Heeren","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.09.003_bb0140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2016.09.003_bb0145","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guerin therapy in bladder cancer","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2016.09.003_bb0150","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716302118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716302118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,15]],"date-time":"2018-07-15T16:03:25Z","timestamp":1531670605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817716302118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":30,"alternative-id":["S0046817716302118"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2016.09.003","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2016.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}